Triple-negative breast cancer: Histological subtypes and immunohistochemical and clinicopathological features

Cancer Science

Volumn 102, Issue 3, 2011, Pages 656-662

  Ishikawa, Yuko ^a,b   Horiguchi, Jun ^b   Toya, Hiroyuki ^a,b   Nakajima, Hiroki ^a   Hayashi, Mitsuhiro ^c   Tagaya, Nobumi ^d   Takeyoshi, Izumi ^b   Oyama, Tetsunari ^a  

^a Departments of Diagnostic Pathology   (Japan)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOKYO MEDICAL UNIVERSITY HACHIOJI MEDICAL CENTER   (Japan)

^d DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CARCINOMA IN SITU; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MEDULLARY CARCINOMA; PATHOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 79951688503     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01858.x     Document Type: Article

References (36)

1. Sasaki Y, Tsuda H. Clinicopathological characteristics of triple-negative breast cancers. Breast Cancer 2009; 16: 254-9.
2. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-81.
3. Iwase H, Kurebayashi J, Tsuda H et al. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer 2010; 17: 118-24.
4. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32.
5. Rakha EA, Elsheikh SE, Aleskandarany MA et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009; 15: 2302-10.
6. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008; 52: 108-18.
7. Tan DS, Marchio' C, Jones RL et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008; 111: 27-44.
8. Podo F, Buydens LM, Degani H et al. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 2010; 4: 209-29.
9. Oakman C, Viale G, Di Leo A. Management of triple negative breast cancer. Breast 2010; 19: 312-21.
10. Liu H, Fan Q, Zhang Z et al. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Hum Pathol 2008; 39: 167-74.
11. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
12. Rodríguez-Pinilla SM, Rodríguez-Gil Y, Moreno-Bueno G et al. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study. Am J Surg Pathol 2007; 31: 501-8.
13. Reis-Filho JS, Milanezi F, Steele D et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006; 49: 10-21.
14. Sasaki Y, Tsuda H, Ueda S et al. Histological differences between invasive ductal carcinoma with a large central acellular zone and matrix-producing carcinoma of the breast. Pathol Int 2009; 59: 390-4.
15. Tsuda H, Takarabe T, Hasegawa T, Murata T, Hirohashi S. Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones. Hum Pathol 1999; 30: 1134-9.
16. Tsuda H, Takarabe T, Hasegawa F, Fukutomi T, Hirohashi S. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 2000; 24: 197-202.
17. Umemura S, Takekoshi S, Suzuki Y, Saitoh Y, Tokuda Y, Osamura RY. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression. Oncol Rep 2005; 14: 337-43.
18. Livasy CA, Perou CM, Karaca G et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 2007; 38: 197-204.
19. Williams DJ, Cohen C, To TV et al. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray. Hum Pathol 2009; 40: 1176-81.
20. Japanese Breast Cancer Society. Histological classification of breast tumor. In: General Rules for Clinical and Pathological Recording of Breast Cancer, 16th edn. Tokyo: Kanehara, 2008; 18-24.
21. Da Silva L, Clarke C, Lakuhani SR. Demystifying basal-like breast carcinomas. J Clin Pathol 2007; 60: 1328-32.
22. Fulford LG, Easton DF, Reis-Filho JS et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006; 49: 22-34.
23. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006; 25: 5846-53.
24. Orlando L, Renne G, Rocca A et al. Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype Ann Oncol 2005; 16: 1094-9.
25. Ridolfi RL, Rosen PP, Port A, Kinne D, Miké V. Medullary carcinoma of the breast: a clinicopathologic study with 10year follow-up. Cancer 1977; 40: 1365-85.
26. Tavassoéli FA, Devilee P. World Health Organization Classification of Tumors of the Breast and Female Genital Organs. Lyon, France: IARC Press, 2004; 13-59.
27. Dabbs DJ, Chivukula M, Carter G, Bhargava R. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol 2006; 19: 1506-11.
28. Kreike B, van Kouwenhove M, Horlings H et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007; 9: R65 (doi:); 1-14.
29. Bryan BB, Schnitt SJ, Collins LC et al. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 2006; 19: 617-21.
30. Park K, Han S, Kim HJ, Kim J, Shin E. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 2006; 48: 702-7.
31. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J Pathol 2005; 205: 248-54.
32. Bhargava R, Striebel J, Beriwal S et al. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol 2009; 2: 444-55.
33. Rapin V, Contesso G, Mouriesse H et al. Medullary breast carcinoma. A reevaluation of 95 cases of breast cancer with inflammatory stroma. Cancer 1988; 61: 2503-10.
34. Rakha EA, Aleskandarany M, El-Sayed ME et al. The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer 2009; 45: 1780-7.
35. Xu R, Feiner H, Li P et al. Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast. Arch Pathol Lab Med 2003; 127: 1458-64.
36. Yamaguchi R, Furusawa H, Nakahara H et al. Clinicopathological study of invasive ductal carcinoma with large central acellular zone: special reference to magnetic resonance imaging findings. Pathol Int 2008; 58: 26-30.